Yool Andrea J, Ramesh Sunita
Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia.
College of Science and Engineering, Flinders University, Adelaide, SA, Australia.
Front Pharmacol. 2020 Mar 27;11:358. doi: 10.3389/fphar.2020.00358. eCollection 2020.
The highly invasive nature of glioblastoma imposes poor prospects for patient survival. Molecular evidence indicates glioblastoma cells undergo an intriguing expansion of phenotypic properties to include neuron-like signaling using excitable membrane ion channels and synaptic proteins, augmenting survival and motility. Neurotransmitter receptors, membrane signaling, excitatory receptors, and Ca responses are important candidates for the design of customized treatments for cancers within the heterogeneous central nervous system. Relatively few published studies of glioblastoma multiforme (GBM) have evaluated pharmacological agents targeted to signaling pathways in limiting cancer cell motility. Transcriptomic analyses here identified classes of ion channels, ionotropic receptors, and synaptic proteins that are enriched in human glioblastoma biopsy samples. The pattern of GBM-enriched gene expression points to a major role for glutamate signaling. However, the predominant role of AMPA receptors in fast excitatory signaling throughout the central nervous system raises a challenge on how to target inhibitors selectively to cancer cells while maintaining tolerability. This review critically evaluates a panel of ligand- and voltage-gated ion channels and synaptic proteins upregulated in GBM, and the evidence for their potential roles in the pathological disease progress. Evidence suggests combinations of therapies could be more effective than single agents alone. Natural plant products used in traditional medicines for the treatment of glioblastoma contain flavonoids, terpenoids, polyphenols, epigallocatechin gallate, quinones, and saponins, which might serendipitously include agents that modulate some classes of signaling compounds highlighted in this review. New therapeutic strategies are likely to exploit evidence-based combinations of selected agents, each at a low dose, to create new cancer cell-specific therapeutics.
胶质母细胞瘤的高度侵袭性导致患者生存前景不佳。分子证据表明,胶质母细胞瘤细胞的表型特性会发生有趣的扩展,包括利用可兴奋膜离子通道和突触蛋白进行类似神经元的信号传导,从而提高生存率和运动能力。神经递质受体、膜信号传导、兴奋性受体和钙反应是为异质性中枢神经系统内的癌症设计定制治疗方案的重要候选因素。相对较少的已发表研究评估了针对信号通路以限制癌细胞运动的药物制剂。此处的转录组分析确定了在人类胶质母细胞瘤活检样本中富集的离子通道、离子型受体和突触蛋白类别。胶质母细胞瘤富集基因表达模式表明谷氨酸信号传导起主要作用。然而,AMPA受体在整个中枢神经系统快速兴奋性信号传导中的主要作用对如何在保持耐受性的同时将抑制剂选择性地靶向癌细胞提出了挑战。本综述批判性地评估了一组在胶质母细胞瘤中上调的配体门控和电压门控离子通道以及突触蛋白,以及它们在病理疾病进展中潜在作用的证据。有证据表明联合治疗可能比单一药物更有效。传统医学中用于治疗胶质母细胞瘤的天然植物产品含有黄酮类化合物、萜类化合物、多酚、表没食子儿茶素没食子酸酯、醌类和皂苷,其中可能偶然包含调节本综述中强调的某些信号化合物类别的药物。新的治疗策略可能会利用基于证据的选定药物组合,每种药物剂量较低,以创造新的癌细胞特异性疗法。